It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Streptococcus pneumoniae causes substantial mortality among children under 5-years-old worldwide. Polysaccharide conjugate vaccines (PCVs) are highly effective at reducing vaccine serotype disease, but emergence of non-vaccine serotypes and persistent nasopharyngeal carriage threaten this success. We investigated the hypothesis that following vaccine, adapted pneumococcal genotypes emerge with the potential for vaccine escape. We genome sequenced 2804 penumococcal isolates, collected 4-8 years after introduction of PCV13 in Blantyre, Malawi. We developed a pipeline to cluster the pneumococcal population based on metabolic core genes into “Metabolic genotypes” (MTs). We show that S. pneumoniae population genetics are characterised by emergence of MTs with distinct virulence and antimicrobial resistance (AMR) profiles. Preliminary in vitro and murine experiments revealed that representative isolates from emerging MTs differed in growth, haemolytic, epithelial infection, and murine colonisation characteristics. Our results suggest that in the context of PCV13 introduction, pneumococcal population dynamics had shifted, a phenomenon that could further undermine vaccine control and promote spread of AMR.
Pneumococcal vaccination has been shown to promote emergence of non-vaccine S. pneumoniae serotypes. Here, the authors use data from Malawi to investigate whether vaccine introduction also results in changes in metabolic, virulence, and antimicrobial resistance profiles of circulating strains.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 Tel Aviv University, Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicine, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Tel Aviv University, Porter School of the Environment and Earth Sciences, Faculty of Exact Sciences, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
2 Malawi Liverpool Wellcome Programme, Blantyre, Malawi (GRID:grid.12136.37); University College London, Mucosal Pathogens Research Group, Research Department of Infection, Division of Infection & Immunity, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201); University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands (GRID:grid.7692.a) (ISNI:0000 0000 9012 6352)
3 Malawi Liverpool Wellcome Programme, Blantyre, Malawi (GRID:grid.7692.a); University College London, Mucosal Pathogens Research Group, Research Department of Infection, Division of Infection & Immunity, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201)
4 Kamuzu University of Health Sciences, Blantyre, Malawi (GRID:grid.517969.5)
5 University College London, Mucosal Pathogens Research Group, Research Department of Infection, Division of Infection & Immunity, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201)
6 University College London, Mucosal Pathogens Research Group, Research Department of Infection, Division of Infection & Immunity, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201); Lancaster University, Faculty of Health and Medicine, Biomedical and Life Sciences, Lancaster, United Kingdom (GRID:grid.9835.7) (ISNI:0000 0000 8190 6402); Lancaster University, Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster, United Kingdom (GRID:grid.9835.7) (ISNI:0000 0000 8190 6402)
7 Malawi Liverpool Wellcome Programme, Blantyre, Malawi (GRID:grid.9835.7)
8 Malawi Liverpool Wellcome Programme, Blantyre, Malawi (GRID:grid.83440.3b); University of Liverpool, Clinical Infection, Microbiology and Immunology, Institute of Infection Veterinary & Ecological Science, Liverpool, United Kingdom (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)
9 University College London, UCL Respiratory, Division of Medicine, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201)
10 University of Oxford, Department of Zoology, Oxford, United Kingdom (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Biomedical Research Centre, Universidade Católica Portuguesa, Faculty of Medicine, Lisbon, Portugal (GRID:grid.7831.d) (ISNI:0000 0001 0410 653X)
11 University of Oxford, Department of Zoology, Oxford, United Kingdom (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
12 University of Liverpool, Clinical Infection, Microbiology and Immunology, Institute of Infection Veterinary & Ecological Science, Liverpool, United Kingdom (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)
13 Malawi Liverpool Wellcome Programme, Blantyre, Malawi (GRID:grid.4991.5); University College London, Mucosal Pathogens Research Group, Research Department of Infection, Division of Infection & Immunity, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201)